验证慢性期慢性髓细胞白血病互滥替尼治疗失败评分(IMTF)在实际临床应用中的准确性。
Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice.
发表日期：2023 Sep 10
作者：
Claudia Ielo, Emilia Scalzulli, Ida Carmosino, Sara Pepe, Maria Laura Bisegna, Maurizio Martelli, Massimo Breccia
来源：
MEDICINE & SCIENCE IN SPORTS & EXERCISE
摘要：
过去十年间，慢性髓系白血病（CML）患者的预后得到了改善。临床预后评分系统旨在提供关于长期生存的信息，但并不根据基线情况确定那些需要严密监测以因应失败风险增加的患者子群。目前，第一代酪氨酸激酶抑制剂（TKI）伊马替尼仍广泛作为一线治疗用药：最近，提出了伊马替尼治疗失败（IMTF）评分以识别无失败生存情况。本研究旨在验证此指标在一大批使用伊马替尼进行治疗的患者中的有效性。
The outcome of chronic myeloid leukemia (CML) patients improved in the last decade. Clinical prognostic scoring systems aim to provide information about survival in the long-term, without determining from baseline the subset of patients who require a strictly monitoring because at increased risk of failure. Imatinib, the first-generation tyrosine kinase inhibitor (TKI), is still widely used as frontline treatment: recently, the imatinib therapy failure (IMTF) score was proposed to identify the failure free survival. Aim of our study was to validate this index in a large cohort of patients treated with imatinib.